XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Equity
 3 Months Ended
Mar. 31, 2024
Stockholders Equity Note [Abstract]  
Equity

Note 17. Equity

 

On April 27, 2022, the Company’s board of directors approved a share repurchase program authorizing the purchase of shares of Chemours’ issued and outstanding common stock in an aggregate amount not to exceed $750, plus any associated fees or costs in connection with the Company’s share repurchase activity (the “2022 Share Repurchase Program”). Under the 2022 Share Repurchase Program, shares of Chemours’ common stock can be purchased in the open market from time to time, subject to management’s discretion, as well as general business and market conditions. The Company’s 2022 Share Repurchase Program became effective on April 27, 2022 and is scheduled to continue through the earlier of its expiration on December 31, 2025 or the completion of repurchases up to the approved amount. The program may be suspended or discontinued at any time. All common shares purchased under the 2022 Share Repurchase Program are expected to be held as treasury stock and accounted for using the cost method.

 

The following table sets forth the Company’s share repurchase activity under the 2022 Share Repurchase Program for the three months ended March 31, 2024 and 2023, respectively.

 

 

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

Total number of shares purchased

 

 

—

 

 

 

386,000

 

Total amount for shares purchased

 

$

—

 

 

$

13

 

Average price paid per share

 

$

—

 

 

$

33.77

 

 

Through March 31, 2024, the Company purchased a cumulative 10,342,722 shares of Chemours’ issued and outstanding common stock under the 2022 Share Repurchase Program, which amounted $309 at an average share price of $29.90 per share. The aggregate amount of Chemours’ common stock that remained available for purchase under the 2022 Share Repurchase Program at March 31, 2024 was $441.